Combination of vascular disrupting agents and ionizing radiation.
作者： Céline Clémenson , Cyrus Chargari , Eric Deutsch
DOI: 10.1016/J.CRITREVONC.2012.10.002
关键词:
摘要: Vascular disrupting agents (VDAs) are a relatively new class of drugs that target tumor vasculature and induce blood flow shutdown subsequent necrosis in the core. The first generation these is actively evaluated clinical trials, whereas molecules developed order to enhance efficacy overcome resistance mechanisms. VDA used as single agent only cause moderate growth delay. So, strategy aiming at combining conventional cancer treatments undergoing extensive investigations. A special emphasis has been put on combination with chemotherapeutic agents. Besides, numerous preclinical studies have also clearly established association radiotherapy can improve antitumor treatment may lead therapeutic gain. However, up date, there lack trials evaluating such combinations, it would be great interest since widely anticancer treatment.
elsevier.com
sci-hub.se 参考文章(115)
Deborah Citrin, Kevin Camphausen, Advancement of antiangiogenic and vascular disrupting agents combined with radiation. Cancer treatment and research. ,vol. 139, pp. 150- 168 ,(2008) , 10.1007/978-0-387-36744-6_8
George Pettit, C. S. Parkins, S. A. Hill, D. J. Chaplin, Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. The British journal of cancer. Supplement. ,vol. 27, ,(1996)
M. R. Horsman, R. Murata, T. Breidahl, F. U. Nielsen, R. J. Maxwell, H. Stødkiled-Jørgensen, J. Overgaard., Combretastatins Novel Vascular targeting Drugs for Improving Anticancer therapy Springer, Boston, MA. pp. 311- 323 ,(2000) , 10.1007/978-1-4615-4221-6_26
Kazuo Kubota, Katsuyoshi Hori, Yasufumi Sato, Sachiko Saito, Stoppage of blood flow in 3-methylcholanthrene-induced autochthonous primary tumor due to a novel combretastatin A-4 derivative, AC7700, and its antitumor effect. Medical Science Monitor. ,vol. 7, pp. 26- 33 ,(2001)
W Landuyt, O Verdoes, D.O Darius, M Drijkoningen, S Nuyts, J Theys, L Stockx, W Wynendaele, J.F Fowler, G Maleux, W Van den Bogaert, J Anné, A van Oosterom, P Lambin, Vascular targeting of solid tumours European Journal of Cancer. ,vol. 36, pp. 1833- 1843 ,(2000) , 10.1016/S0959-8049(00)00173-8
Geoff Delaney, Susannah Jacob, Carolyn Featherstone, Michael Barton, The role of radiotherapy in cancer treatment Cancer. ,vol. 104, pp. 1129- 1137 ,(2005) , 10.1002/CNCR.21324
Xuan Ren, Mei Dai, Li-Ping Lin, Pui-Kai Li, Jian Ding, Anti-angiogenic and vascular disrupting effects of C9, a new microtubule-depolymerizing agent. British Journal of Pharmacology. ,vol. 156, pp. 1228- 1238 ,(2009) , 10.1111/J.1476-5381.2009.00112.X
Chryso Kanthou, Gillian M. Tozer, Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies. International Journal of Experimental Pathology. ,vol. 90, pp. 284- 294 ,(2009) , 10.1111/J.1365-2613.2009.00651.X
Shona T. Dougherty, Sean E. Walker, Peter D. Davis, Graeme J. Dougherty, The Novel Vascular Disrupting Agent ANG501 Induces Cell Cycle Arrest and Enhances Endothelial Cell Sensitivity to Radiation Cancer Growth and Metastasis. ,vol. 2009, pp. 1- 10 ,(2009) , 10.4137/CGM.S2596
Vivien E. Prise, George R. Pettit, Graham G. Dark, Sally A. Hill, Dai J. Chaplin, Gillian M. Tozer, Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature Cancer Research. ,vol. 57, pp. 1829- 1834 ,(1997)